25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
As a result of the COVID-19 (coronavirus) pandemic, the Federal Trade Commission’s Premerger Notifi...
Read More >
The COVID-19 pandemic has heavily disrupted M&A activity around the globe and many projects have bee...
Read More >
There are many ways to run afoul of labor laws and spook your investors—one of the most common for ...
Read More >
Key Takeaways: - FTC commissioners have seven year terms and cannot be removed for political or pol...
Read More >
Our previous posts have stressed the critical importance of buy-sell agreements for both majority ow...
Read More >
Now that 2020 is almost here, corporations should be aware of IRS reporting requirements regarding c...
Read More >